Author

M. Caligiuri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

A. Li· 2 shared B. M. Barker· 2 shared H. L. Mead· 2 shared J. Yu· 2 shared J. Zhang· 2 shared P. Keim· 2 shared S. Jaramillo· 2 shared W. Dong· 2 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Li

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant

J. Yu, W. Dong, J. Wang, L. Tian, J. Zhang, H. L. Mead, S. Jaramillo, A. Li, R. Zumwalt, S. P. J. Whelan, E. Settles, P. Keim, B. M. Barker, M. Caligiuri

This study shows FXa cleaves SARS-CoV-2 spike protein, blocking viral entry, but B.1.1.7 variant is resistant, and FXa inhibitors like rivaroxaban reduce this protection.

bioRxiv · Jun 7, 2021 · PreprintMicrobiology

The K18-hACE2 Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-19 in Response to Infectious Dose of SARS-CoV-2 Virus

J. Yu, W. Dong, A. Li, J. Zhang, M. Caligiuri, S. Jaramillo, H. L. Mead, N. E. Stone, A. Jones, D. R. Kollath, V. K. Coyne, M. Yearsley, L.-S. Wang, B. M. Barker, P. Keim, T. Barr

The paper characterizes the K18-hACE2 mouse model's response to different SARS-CoV-2 doses, showing dose-dependent disease severity and recovery, and compares it to human COVID-19 pathology.

bioRxiv · May 8, 2021Microbiology